What should you know about lobular carcinoma in situ of left breast?

LCIS is often not felt as a lump and may be discovered when tissue is sampled for another imaging finding. The cells are contained within the lobules; the label does not mean that cancer has spread through the breast. The left-sided location identifies where the biopsy finding was seen, while risk discussions may consider both breasts.

The pathology subtype matters. Classic LCIS and more atypical forms may lead to different recommendations, particularly when the imaging and biopsy findings do not match. Your team may review the slides, examine the surrounding tissue, and decide whether more sampling is needed.

Care commonly involves an individual surveillance plan with breast examination and imaging at intervals chosen for your risk profile. Some people discuss risk-reducing endocrine therapy, which can lower the chance of certain hormone-sensitive breast cancers but may cause side effects and is not right for everyone.

Keep copies of the pathology and imaging reports, mention relatives with breast or ovarian cancer, and tell the team about medicines, pregnancy plans, bone health, and clotting history. Lifestyle measures such as regular activity, avoiding tobacco, and limiting alcohol can support general health without replacing clinical follow-up.

Arrange prompt assessment for a new breast or underarm lump, persistent focal change, nipple inversion, bloody discharge, skin dimpling, or unexplained swelling. These changes do not establish cancer, but they deserve examination even when you have a previous LCIS diagnosis. Seek urgent help for severe breathing difficulty or sudden neurological symptoms.

Ask which LCIS subtype was found, whether the imaging and pathology agree, and whether another biopsy or surgery is advised. Ask what surveillance schedule fits both breasts, how your family history changes the plan, and whether risk-reducing endocrine therapy is suitable for your health and priorities.